{"id":950253,"date":"2026-04-09T11:50:09","date_gmt":"2026-04-09T15:50:09","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/"},"modified":"2026-04-09T11:50:09","modified_gmt":"2026-04-09T15:50:09","slug":"immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/","title":{"rendered":"Immix Biopharma to Participate in the Jefferies Global Healthcare Conference"},"content":{"rendered":"
\n

LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (\u201cImmixBio\u201d, \u201cCompany\u201d, \u201cWe\u201d or \u201cUs\u201d or \u201dIMMX\u201d), the global leader in relapsed\/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY.<\/p>\n

The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Jefferies representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section.<\/p>\n

\n About Immix Biopharma, Inc.<\/b>
\n
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed\/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that\u2019s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a \u201cdigital filter\u201d that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed\/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.<\/p>\n

\n Contacts<\/b>
\n
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com<\/p>\n

\n Company Contact
<\/b>irteam@immixbio.com<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (\u201cImmixBio\u201d, \u201cCompany\u201d, \u201cWe\u201d or \u201cUs\u201d or \u201dIMMX\u201d), the global leader in relapsed\/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY. The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Jefferies representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section. About Immix Biopharma, Inc. Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed\/refractory AL Amyloidosis. AL Amyloidosis is a … <\/p>\n

Continue reading “Immix Biopharma to Participate in the Jefferies Global Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-950253","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nImmix Biopharma to Participate in the Jefferies Global Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immix Biopharma to Participate in the Jefferies Global Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (\u201cImmixBio\u201d, \u201cCompany\u201d, \u201cWe\u201d or \u201cUs\u201d or \u201dIMMX\u201d), the global leader in relapsed\/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY. The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Jefferies representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section. About Immix Biopharma, Inc. Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed\/refractory AL Amyloidosis. AL Amyloidosis is a … Continue reading "Immix Biopharma to Participate in the Jefferies Global Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-09T15:50:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjY4MCM3NTI2ODY3IzUwMDA5ODEwNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immix Biopharma to Participate in the Jefferies Global Healthcare Conference\",\"datePublished\":\"2026-04-09T15:50:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\\\/\"},\"wordCount\":263,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjY4MCM3NTI2ODY3IzUwMDA5ODEwNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\\\/\",\"name\":\"Immix Biopharma to Participate in the Jefferies Global Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjY4MCM3NTI2ODY3IzUwMDA5ODEwNA==\",\"datePublished\":\"2026-04-09T15:50:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjY4MCM3NTI2ODY3IzUwMDA5ODEwNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY4NjY4MCM3NTI2ODY3IzUwMDA5ODEwNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immix Biopharma to Participate in the Jefferies Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immix Biopharma to Participate in the Jefferies Global Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Immix Biopharma to Participate in the Jefferies Global Healthcare Conference - Market Newsdesk","og_description":"LOS ANGELES, CA, April 09, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (\u201cImmixBio\u201d, \u201cCompany\u201d, \u201cWe\u201d or \u201cUs\u201d or \u201dIMMX\u201d), the global leader in relapsed\/refractory AL Amyloidosis, today announced that it will participate and host institutional investor meetings at the Jefferies Global Healthcare Conference being held June 2-4, 2026 in New York, NY. The Company will be available for one-on-one meetings during the conference. Interested investors should contact their Jefferies representative to request meetings. A link to access the replay, when available, will be posted to the Immix website on the Presentation & Events page under the Investors section. About Immix Biopharma, Inc. Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed\/refractory AL Amyloidosis. AL Amyloidosis is a … Continue reading \"Immix Biopharma to Participate in the Jefferies Global Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-09T15:50:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjY4MCM3NTI2ODY3IzUwMDA5ODEwNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immix Biopharma to Participate in the Jefferies Global Healthcare Conference","datePublished":"2026-04-09T15:50:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/"},"wordCount":263,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjY4MCM3NTI2ODY3IzUwMDA5ODEwNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/","name":"Immix Biopharma to Participate in the Jefferies Global Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjY4MCM3NTI2ODY3IzUwMDA5ODEwNA==","datePublished":"2026-04-09T15:50:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjY4MCM3NTI2ODY3IzUwMDA5ODEwNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY4NjY4MCM3NTI2ODY3IzUwMDA5ODEwNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immix-biopharma-to-participate-in-the-jefferies-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immix Biopharma to Participate in the Jefferies Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/950253","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=950253"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/950253\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=950253"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=950253"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=950253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}